Inhibition of P-selectin–PSGL-1 interaction by inclacumab vs crizanlizumab. Cell-based adhesion assays were conducted to assess the inhibition of adhesion of P-selectin–expressing cells to PSGL-1 by different concentrations of inclacumab or crizanlizumab. (A-B) Next, dose response curves were created, and P-selectin inhibition potencies of 2 mAbs were determined by parallel line analyses, as described in “Methods.” Measured potencies were 98.0% for crizanlizumab (95% CI, 85.2-112.7) in panel A and 26.2% for inclacumab (95% CI, 20.7-32.6) in panel B, determined relative to a crizanlizumab reference standard, including the determined CI. Refer to “Methods” for details on the experimental analysis. CI, confidence interval; ln, natural logarithm.